XML 22 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations (Discontinued Operations: Revenue, Assets and Liabilities) (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating expenses:    
Earnings from discontinued operations $ 0us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax $ 625us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
BioSciences    
Revenues:    
Bioscience product sales and services   9,212us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Cost of revenues:    
Cost of bioscience product sales and services   3,340us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Gross margin   5,872us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Operating expenses:    
Selling and marketing   3,210sqnm_DisposalGroupIncludingDiscontinuedOperationSellingandMarketing
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Research and development   1,372sqnm_DisposalGroupIncludingDiscontinuedOperationResearchandDevelopment
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
General and administrative   287us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Restructuring costs   19sqnm_DisposalGroupIncludingDiscontinuedOperationRestructuringCosts
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Total operating expenses   4,888us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Earnings from discontinued operations   984us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Other income, net   71sqnm_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Earnings from discontinued operations before income taxes   1,055us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Income tax expense   430us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember
Earnings from discontinued operations   $ 625us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= sqnm_SequenomBioscienceMember